Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Arfolitixorin - Isofol Medical

Next Previous
X
Search
Drug Profile

Arfolitixorin - Isofol Medical

Alternative Names: 6R-MTHF; [6R] 5,10-methylenetetrahydrofolate; [6R]-5,10-methylene-THF acid; Arfolitixorin; Arfolitixorin hemisulfate; ISO-901; Modufolin; Modulfolin; SP-05

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Eprova
  • Developer Isofol Medical; Oncosyne
  • Class 3-ring heterocyclic compounds; Antineoplastics; Chemoprotectants; Chemosensitisers; Folic acids; Imidazolidines; Pyrimidinones; Small molecules; Tetrahydrofolates
  • Mechanism of Action Antimetabolites; Thymidylate synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Colorectal cancer
  • Phase II Osteosarcoma
  • Phase I/II Liver metastases; Rectal cancer
  • Preclinical Cancer

Most Recent Events

  • 16 Jul 2024 Pharmacodynamics data from a preclinical trial in Colorectal cancer released by Isofol Medical
  • 05 Jul 2024 Isofol Medical plans to files a CTA application with the regulatory authorities for phase I/II trial in Colorectal cancer by the end of 2024
  • 05 Jul 2024 Isofol Medical and Solasia Pharma plans a phase Ib/II trial (First line therapy, Metastatic disease, Combination therapy) by the end of 2024

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top